Bioorganic & Medicinal Chemistry Letters 22 (2012) 2359

Contents lists available at SciVerse ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Erratum

Erratum to "Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes" [Bioorg. Med. Chem. Lett. 22 (2012) 1464–1468]

Jon M. Sutton [a,*], David E. Clark [a], Stephen J. Dunsdon [a], Garry Fenton [a], Amanda Fillmore [a], Neil V. Harris [a], Chris Higgs [a], Chris A. Hurley [a], Sussie L. Krintel [a], Robert E. MacKenzie [a], Alokesh Duttaroy [b], Eric Gangl [b], Wiesia Maniara [b], Richard Sedrani [c], Kenji Namoto [c], Nils Ostermann [c], Bernd Gerhartz [c], Finton Sirockin [c], Jörg Trappe [c], Ulrich Hassiepen [c], Daniel K. Baeschlin [c,*]

[a] *Argenta Discovery 2009 Ltd, Harlow CM19 5TR, UK*
[b] *Novartis Institutes for BioMedical Research, Cambridge, MA, USA*
[c] *Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland*

The publisher regrets that Scheme 2 was published incorrectly. The corrected scheme appears here.



Scheme 2. Synthesis of 7-cyanodeazaxanthines. (a) BnNCO, Pyr, rt, 18 h, (56–100%); (b) NaOMe, DMF, 70 °C, 4 h, (89–96%); (c) MeI, K_2CO_3, DMF, rt, 4 h, (87–100%); (d) BBr_3, xylene, reflux, 6 h, (85–100%); (e) Br_2, AcOH, 45 °C, 18 h. (68–90%); (f) Boc diamine, *N*-methylmorpholine, DMA, μ-wave, 160 °C, 20 min, (36–86%); (g) ammonium formate, 10% Pd/C, 75 °C, 30 min, (60–90%); (h) R^1Br, DIPEA, DMF, 60 °C, (25–48%); (i) R^2Br, K_2CO_3, DMF, rt, 18 h, (75–95%); (j) TFA/DCM [1:1], rt, 1 h, (75–93%).

☆ DOI of original article: 10.1016/j.bmcl.2011.11.054
* Corresponding authors.
E-mail address: jon.sutton@glpg.com (J.M. Sutton).

doi:10.1016/j.bmcl.2012.01.109